新型放射性核素骨显像剂的应用和进展  

The Application and Progress of New Type Radionuclide Bone Imaging Agents

作　　者：颜新宇[1] 颜玉班 

机构地区：[1]重庆医科大学附属第二医院血液内科,重庆400010 [2]枣庄市峄城区人民医院CT室,山东枣庄277300

出　　处：《医学综述》2011年第8期1232-1235,共4页Medical Recapitulate

摘　　要：全身放射性核素骨显像在早期发现骨骼系统疾病中起着非常重要的作用,而现有的骨显像剂由于自身的缺陷,已不能满足骨骼疾病诊断和治疗的需要。因此,大量新型骨显像剂不断涌现以期填补其不足。99Tcm-乙二胺四甲撑膦酸、153Sm乙-二胺四甲撑膦酸和99Tcm-亚甲基氨基二膦酸具有很好的亲骨性,而177Lu乙-二胺四甲撑膦酸、99Tcm(Ⅴ)-二巯基丁二酸、99Tcm-唑来膦酸、99Tcm-毫微胶体和18F氟-化钠在单独骨病上效果明显。传统改进的膦酸盐、亲和性强的生物制剂蛋白和胆碱,以及性质稳定的化学物质氟和甲缩醛等新型骨显像剂都从不同角度上提升力骨骼成像的作用和价值。Systemic radionuclide bone imaging play a very important role in the early detection of skeletal system diseases.The existing bone imaging agents,due to their intrinsic defects,cannot meet the needs of diagnosis and treatment.Therefore,many new bone imaging agents are emerging to fill the gap.99Tcm-HEDTMP,153Sm-HEDTMP,and 99Tcm-AMDP have good pro-bone abilities,whilst 177Lu-EDTMP,99Tcm（Ⅴ）-DMSA,99Tcm-ZL,99Tcm-nanocolloid,and 18F-NaF are advantageous in single bone disease.The conventional modified phosphonates,high-affinity biological agents protein,and stable chemical substances,such as choline,fluoride,and methylal enhance the role and value of bone imaging from various aspects.

关 键 词：放射性核素骨显像剂 骨骼成像 膦酸盐 生物制剂 

分 类 号：R445.5[医药卫生—影像医学与核医学]